Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Clinical trial NCT01177397 · COMPLETED

Trial details

NCT number: NCT01177397
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Diffuse Large B-Cell Lymphoma Glioblastoma Multiforme Hepatocellular Carcinoma Non-Small Cell Lung Cancer Neuroendocrine Tumors of Non-Pancreatic Origin Hormone Receptor-Positive Breast Cancer

Start date: 2010-07-20
Primary completion: 2016-11-15
Enrollment: 226

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.